Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study)
Gerdts E et al. – During systematic antihypertensive treatment in hypertensive pts with electrocardiographic left ventricular (LV) hypertrophy, lower in-treatment pulse pressure (PP) was associated with lower in-treatment LV function and cardiac output as well as higher rate of cardiovascular events Methods- Study of associations of in-treatment PP with LV systolic function and cardiovascular events
- Subjects: 883 pts with electrocardiographic LV hypertrophy during 4.8 yrs of randomized losartan- or atenolol-based treatment
- Echocardiographic substudy of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
Results- Both treatments similarly reduced PP
- In different multiple regression models, lower in-treatment PP independently associated with lower in-treatment LV ejection fraction, stress-corrected midwall shortening, stroke volume, and cardiac index
- In time-varying Cox regression models, 10 mmHg lower in-treatment PP associated with 28% higher rate of cardiovascular events
- Association independent of in-treatment LV mass and ejection fraction, history of ischemic heart disease, Framingham risk score and study treatment allocation
[more...]
|
|
|
